Polyphenolics Issued Patent for MegaNatural®-BP Grape Seed Extract

BURNSVILLE, Minn.The U.S. Patent and Trademark Office issued Patent No.7,767,235 to Constellation Brands Inc., in connection with its Polyphenolics division, for its MegaNatural®-BP grape seed extract, which has been shown through research and human clinical trials to support healthy blood pressure and to benefit those diagnosed with metabolic syndrome and/or the conditions that comprise metabolic syndrome.  

The patent covers the ingredient with a molecular composition that is easily absorbed by the body and migrates to endothelial for improved vasodilation effect. The patent also covers the final ingredient, MegaNatural-BP, which may be formulated into dietary supplements, including capsules, tablets, powders, solutions, gels, suspensions, creams, etc. MegaNatural-BP may be added to nutraceuticals, as well as used to formulate functional foods and beverages, and medical foods. MegaNatural-BP has been shown to help control blood pressure within the normal range by improving the flexibility of blood vessel walls. It has also been shown to be effective in lowering blood pressure in patients diagnosed with metabolic syndrome, a cluster of conditions that includes increased blood pressure, elevated insulin levels, excess body fat and elevated cholesterol levels.

We are extremely excited about receiving this patent as we strongly believe in this groundbreaking innovation and its potential for helping to protect Americas cardiovascular health," said Anil Shrikhande, Ph.D., president of Polyphenolics. We remain committed to providing our customers and consumers with a superior product supported by extensive human clinical research at University of California, Davis."